References for Appendix 5 and reasons for exclusion
Not randomised controlled trial or randomised comparison
Adler L, Duncan E, Reiter S, Angrist B, Peselow E, Rotrosen J. Effects of calcium-channel antagonists on tardive dyskinesia and psychosis. Psychopharmacol Bull 1988;24:421–5.
Albus M, Naber D, Muller-Spahn F, Douillet P, Reinertshofer T, Ackenheil M. Tardive dyskinesia: relation to computer-tomographic, endocrine, and psychopathological variables. Biol Psychiatry 1985;20:1082–9.
Alexander PE, Van Kammen DP, Bunney WE. Serum calcium and magnesium in schizophrenia: relationship to clinical phenomena and neuroleptic treatment. Br J Psychiatry 1978;133:143–9.
Alexander PE, Van Kammen DP, Bunney WE Jr. Serum calcium and magnesium levels in schizophrenia. II. Possible relationship to extrapyramidal symptoms. Arch Gen Psychiatry 1979;36:1372–7.
Ananth JV, Ban TA, Lehmann HE. An uncontrolled study with thiopropazate in the treatment of persistent dyskinesia. Psychopharmacol Bull 1977;13:9.
Anderson BG, Reker D, Ristich M, Friedman E, Banay-Schwartz M, Volavka J. Lecithin treatment of tardive dyskinesia – a progress report. Psychopharmacol Bull 1982;18:87–8.
Yackulic CF, Anderson BG, Reker D, Webb E, Volavka J. The safety of lecithin diet supplementation in schizophrenic patients. Biol Psychiatry 1982;17:1445–8.
Andersson U, Häggström JE, Nilsson MI, Widerlöv E. Remoxipride, a selective dopamine D2 receptor antagonist, in tardive dyskinesia. Psychopharmacology 1988;94:167–71.
Asher SW, Aminoff MJ. Tetrabenazine and movement disorders. Neurology 1981;31:1051–4.
Asnis GM, Sachar EJ, Langer G, Halpern FS, Fink M. Normal prolactin responses in tardive dyskinesia. Psychopharmacology 1979;66:247–50.
Athanassenas G, Papadopoulos E, Kourkoubas A, Tsitourides S, Gabriel J, Hoïdas S, Frangos E. Serum calcium and magnesium levels in chronic schizophrenics. J Clin Psychopharmacol 1983;3:212–16.
Bartels M, Mezger G, Schmalzing G, Schonle PW. Long-term Treatment of Tardive Dyskinesia with Lecithin. Proceedings of the Symposium der Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie, Nuremberg, Germany, 1981.
Bjorndal N, Casey DE, Gerlach J. Enkephalin, morphine, and naloxone in tardive dyskinesia. Psychopharmacology 1980;69:133–6.
Blaha L. [A strategy to reduce the frequency of early dyskinesias under high-dosed haloperidol treatment.] Arzneimittel Forschung 1980;30:1208.
Blum I, Munitz H, Shalev A, Roberts E. Naloxone may be beneficial in the treatment of tardive dyskinesia. Clin Neuropharmacol 1984;7:265–7.
Blum I, Nisipeanu PF, Roberts E. Naloxone in tardive dyskinesia. Psychopharmacology 1987;93:538.
Bowers MB, Moore D, Tarsy D. Tardive dyskinesia: a clinical test of the supersensitivity hypothesis. Psychopharmacology 1979;61:137–41.
Brambilla F, Gessa GL, Sciascia A, Latina A, Maggioni M, Perna GP, et al. Treatment of drug-resistant chronic schizophrenics with an association of neuroleptics and the calcium antagonist nimodipine. Eur Psychiatry 1992;7:177–82.
Branchey MH, Branchey LB, Bark NM, Richardson MA. Lecithin in the treatment of tardive dyskinesia. Commun Psychopharmacol 1979;3:303–7.
Branchey MH, Branchey LB, Richardson MA. Effects of neuroleptic adjustment on clinical condition and tardive dyskinesia in schizophrenic patients. Am J Psychiatry 1981;138:608–12.
Branchey MH, Branchey LB, Richardson MA. Effects of gradual decrease and discontinuation of neuroleptics on clinical condition and tardive dyskinesia. Psychopharmacol Bull 1981;17:118–20.
Buchanan RW, Kirkpatrick B, Summerfelt A, Hanlon TE, Levine J, Carpenter TW Jr. Clinical predictors of relapse following neuroleptic withdrawal. Biol Psychiatry 1992;32:72–8.
Calne DB, Claveria LE, Teychenne PF, Haskayne L, Lodge-Patch IC. Pimozide in tardive dyskinesia. Trans Am Neurol Assoc 1974;99:166–70.
Campbell M, Adams P, Perry R, Spencer EK, Overall JE. Tardive and withdrawal dyskinesia in autistic children: a prospective study. Psychopharmacol Bull 1988;24:251–5.
Armenteros, JL, Adams PB, Campbell M, Eisenberg ZW. Haloperidol-related dyskinesias and pre- and perinatal complications in autistic children. Psychopharmacol Bull 1995;31:363–9.
Campbell M, Armenteros JL, Malone RP, Adams PB, Eisenberg ZW, Overall JE. Neuroleptic-related dyskinesias in autistic children: a prospective longitudinal study. J Am Acad Child Adolesc Psychiatry 1997;36:835–43.
Caroff SN, Campbell EC, Havey J, Sullivan KA, Mann SC, Gallop R. Treatment of tardive dyskinesia with donepezil: a pilot study. J Clin Psychiatry 2001;62:772–5.
Caroff SN, Campbell EC, Havey JC, Sullivan KA, Katz IR, Mann SC. Treatment of tardive dyskinesia with donepezil. J Clin Psychiatry 2001;62:128–9.
Carpenter WT, Rey AC, Stephens JH. Covert dyskinesia in ambulatory schizophrenia. Lancet 1980;2:212–13.
Casey DE, Denny D. Deanol in the treatment of tardive dyskinesia. Am J Psychiatry 1975;132:864–7.
Casey DE, Denney D. Pharmacological characterization of tardive dyskinesia. Psychopharmacology 1977;54:1–8.
Casey DE. Mood alterations during deanol therapy. Psychopharmacology 1979;62:187–91.
Casey DE, Hammerstad JP. Sodium valproate in tardive dyskinesia. J Clin Psychiatry 1979;40:483–5.
Casey DE, Gerlach J, Simmelsgaard H. Sulpiride in tardive dyskinesia. Psychopharmacology 1979;66:73–7.
Casey DE, Gerlach J, Magelund G, Christensen TR. Gamma-acetylenic GABA in tardive dyskinesia. Arch Gen Psychiatry 1980;37:1376–9.
Casey DE, Gerlach J, Magelund G, Christensen TR. Gamma-acetylenic GABA in tardive dyskinesia. Adv Biochem Psychopharmacol 1980;24:577–80.
Casey DE, Korsgaard S, Gerlach J, Jørgensen A, Simmelsgaard H. Effect of des-tyrosine-gamma-endorphin in tardive dyskinesia. Arch Gen Psychiatry 1981;38:158–60.
Casey DE, Korsgaard S, Gerlach J. Des-tyr-gamma-endorphin in Tardive Dyskinesia. Proceedings of the World Congress of Biological Psychiatry, Stockholm, Sweden, 28 June–3 July 1981.
Blum I, Nisipeanu PF, Roberts E, Casey DE, Korsgaard S, Gerlach J. Des-tyr-gamma-endorphin in Tardive Dyskinesia. Proceedings of the 3rd World Congress of Biological Psychiatry, Stockholm, Sweden, 28 June–3 July 1981.
Casey DE. Tardive dyskinesia: what is the natural history? Int Drug Ther Newsl 1983;18:13–16.
Cassady SL, Thaker GK, Tamminga CA. Pharmacologic relationship of anti saccade and dyskinesia in schizophrenic patients. Psychopharmacol Bull 1993;29:236–40.
Chouza C, Romero S, Lorenzo J, Camano JL, Fontana AP, Alterwain P, et al. [Clinical trial of tiapride in patients with dyskinesia (author’s transl).] Sem Hop 1982;58:725–33.
Claveria LE, Teychenne PF, Calne DB, Haskayne L, Petrie A, Pallis CA, Lodge-Patch IC. Tardive dyskinesia treated with pimozide. J Neurol Sci 1975;24:393–401.
Cowen MA, Green M, Bertollo DN, Abbott K. A treatment for tardive dyskinesia and some other extrapyramidal symptoms. J Clin Psychopharmacol 1997;17:190–3.
Crane GE. Tardive dyskinesia in schizophrenic patients treated with psychotropic drugs. Agressologie 1968;9:209–18.
Crane GE, Ruiz P, Kernohan WJ, Wilson W, Royalty N. Effects of drug withdrawal on tardive dyskinesia. Act Nerv Super 1969;11:30–5.
Crane GE. Deanol for tardive dyskinesia. N Engl J Med 1975;292:926.
Curran JP. Management of tardive dyskinesia with thiopropazate. Am J Psychiatry 1973;130:925–7.
Curran DJ, Nagaswami S, Mohan KJ. Treatment of phenothiazine induced bulbar persistent dyskinesia with deanol acetamidobenzoate. Dis Nerv Syst 1975;36:71–3.
Danion JM, Singer L, Tell G, Schechter P. [Gamma-vinyl GABA and tardive dyskinesia: a single-blind study versus placebo.] Ann Med Psychol 1984;142:101–10.
Davis KL, Berger PA, Hollister LE. Letter: Choline for tardive dyskinesia. N Engl J Med 1975;293:152. http://dx.doi.org/10.1056/NEJM197507172930317
Davis KL, Hollister LE, Barchas JD, Berger PA. Choline in tardive dyskinesia and Huntington’s disease. Life Sci 1976;19:1507–15.
Davis KL, Berger PA, Hollister LE. Deanol in tardive dyskinesia. Am J Psychiatry 1977;134:807. http://dx.doi.org/10.1176/ajp.134.7.807
Davis KL, Berger PA. Pharmacological investigations of the cholinergic imbalance hypotheses of movement disorders and psychosis. Biol Psychiatry 1978;13:23–49.
De Silva L, Huang CY. Deanol in tardive dyskinesia. Br Med J 1975;3:466.
Delwaide PJ, Hurlet A. Bromocriptine and buccolinguofacial dyskineasias in patients with senile dementia. A quantitative study. Arch Neurol 1980;37:441–3.
Diamond BI, Borison RL. Basic and clinical studies of neuroleptic-induced supersensitivity psychosis and dyskinesia. Psychopharmacol Bull 1986;22:900–5.
Dixon L, Thaker G, Conley R, Ross D, Cascella N, Tamminga C. Changes in psychopathology and dyskinesia after neuroleptic withdrawal in a double-blind design. Schizophrenia Res 1993;10:267–71.
Duncan E, Adler L, Angrist B, Rotrosen J. Nifedipine in the treatment of tardive dyskinesia. J Clin Psychopharmacol 1990;10:414–16.
Escobar JI, Kemp KF. Letter: Dimethylaminoethanol for tardive dyskinesia. N Engl J Med 1975;292:317–18. http://dx.doi.org/10.1056/NEJM197502062920617
Fahn S. Long Term Treatment of Tardive Dyskinesia with Presynaptically Acting Dopamine-Depleting Agents. In Fahn S, Calne DB, Shoalson I, eds. Advances in Neurology: Experimental Therapeutics of Movement Disorders. New York, NY: Raven Press; 1983. pp. 267–7.
Fahn S. A therapeutic approach to tardive dyskinesia. J Clin Psychiatry 1985;46:19–24.
Falk WE, Wojick JD, Gelenberg AJ. Diltiazem for tardive dyskinesia and tardive dystonia. Lancet 1988;1:824–5.
Fann WE, Lake CR, Gerber CJ, McKenzie GM. Cholinergic suppression of tardive dyskinesia. Psychopharmacologia 1974;37:101–7.
Fann WE, Sullivan JL, Miller RD, McKenzie GM. Deanol in tardive dyskinesia: a preliminary report. Psychopharmacologia 1975;42:135–7.
Fann WE, Stafford JR, Thornby JI, Richman BW. Chronic deanol administration in tardive dyskinesia. Clin Pharmacol Therapeu 1976;19:106.
Ferrari P, Robotti E, Nardini M. [Experimental design of a pilot study on amantadine in the extrapyramidal syndrome induced by neuroleptic drugs.] Boll Chim Farm 1972;111:610–15.
Freeman H, Soni SD. Oxypertine for tardive dyskinesia. Br J Psychiatry 1980;136:522–3.
Freeman HL, Soni SD, Carpenter L. A controlled trial of oxypertine in tardive dyskinesia. International Pharmacopsychiatry 1980;15:281–91.
Freeman HL, Soni SD. Treatment of Tardive Dyskinesia with Oxypertine. Supplement to Progress in Neuropsychopharmacology. Proceedings of the 12th Congress of Collegium Internationale Neuro-psychopharmacologicum, 1980.
Gardos G, Cole JO. Pilot study of cyproheptadine (Periactin) in tardive dyskinesia. Psychopharmacol Bull 1978;14:18–20.
Gardos G, Cole JO, Rapkin RM, LaBrie RA, Baquelod E, Moore P, et al. Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures. Arch Gen Psychiatry 1984;41:1030–5.
Gelenberg AJ, Doller-Wojcik JC, Growdon JH. Choline and lecithin in the treatment of tardive dyskinesia: preliminary results from a pilot study. Am J Psychiatry 1979;136:772–6.
Gerlach J, Thorsen K. The movement pattern of oral tardive dyskinesia in relation to anticholinergic and antidopaminergic treatment. Int Pharmacopsychiatry 1976;11:1–7.
Gerlach J. The relationship between parkinsonism and tardive dyskinesia. Am J Psychiatry 1977;134:781–4.
Gerlach J, Simmelsgaard H. Tardive dyskinesia during and following treatment with haloperidol, haloperidol + biperiden, thioridazine, and clozapine. Psychopharmacology 1978;59:105–12.
Gerlach J, Casey DE. Sulpiride in tardive dyskinesia. Acta Psychiatr Scand Suppl 1984;311:93–102.
Gerlach J, Casey DE. [Dogmatil in delayed dyskinesia.] Sem Hop 1985;61:1369–75.
Bjørndal N, Casey D, Gerlach J. Dopamine antagonist and agonist treatment of tardive dyskinesia. Adv Biochem Psychopharmacol 1980;24:541–5.
Gerlach J, Korsgaard S, Noring U. Primary (Initial) and Secondary (Tardive) Dyskinesia: Effect of Fluperlapine, a New Atypical Neuroleptic Drug. In Usdin E, ed. Catecholamines: Neuropharmacology and Central Nervous System – Therapeutic Aspects. New York, NY: Liss; 1984. pp. 73–8.
Korsgaard S, Noring U, Gerlach J. Fluperlapine in tardive dyskinesia and parkinsonism. Psychopharmacology 1984;84:76–9.
Gibson AC. Sodium valproate and tardive dyskinesia. Br J Psychiatry 1978;133:82.
Gibson AC. Depot Fluphenazine and Tardive Dyskinesia in an Outpatient Population. In Fann WE, Smith RC, Davis JM, Domino EF, eds. Tardive Dyskinesia: Research and Treatment. New York, NY: Spectrum Publications; 1980. pp. 315–24.
Gibson AC. Effect of drug holidays on tardive dyskinesia. In Usdine E, Forrest IS, eds. Phenothiazines and Structurally Related Drugs: Basic and Clinical Studies. New York, NY: Elsevier-North Holland; 1980. pp. 333–6.
Ginsberg DL. Gabapentin reduces neuroleptic-induced tardive dyskinesia. Prim Psychiatry 2003;10:31–2.
Glazer WM, Morre DC, Schooler NR, Brenner LM, Morgenstern H. Tardive dyskinesia: a discontinuation study. Arch Gen Psychiatry 1984;41:623–7.
Glazer WM, Bowers MB, Charney DS, Heninger GR. The effect of neuroleptic discontinuation on psychopathology, involuntary movements, and biochemical measures in patients with persistent tardive dyskinesia. Biol Psychiatry 1989;26:224–33.
Granacher RP, Baldessarini RJ, Cole JO. Deanol for tardive dyskinesia. N Engl J Med 1975;292:926–7.
Grebb JA, Shelton RC, Taylor EH, Bigelow LB. A negative, double-blind, placebo-controlled, clinical trial of verapamil in chronic schizophrenia. Biol Psychiatry 1986;21:691–4.
Growdon JH, Hirsch MJ, Wurtman RJ, Wiener W. Oral choline administration to patients with tardive dyskinesia. N Engl J Med 1977;297:524–7. http://dx.doi.org/10.1056/NEJM197709082971002
Growdon JH. Effects of choline on tardive dyskinesia and other movement disorders. Psychopharmacol Bull 1978;14:55–6.
Wurtman RJ, Growdon JH. Dietary enhancement of CNS neurotransmitters. Hosp Pract 1978;13:71–7.
Haggstrom J. Sulpride in tardive dyskinesia. Curr Therap Res 1980;27:164–9.
Hanus H, Tůma I, Fusek J, Patocka J. [Treatment of tardive dyskinesias with 7-methoxycrine. II.] Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove Suppl 1993;36:47–53.
Heresco-Levy U, Greenberg D, Lerer B, Dasberg H, Brown WA. Trial of maintenance neuroleptic dose reduction in schizophrenic outpatients: two-year outcome. J Clin Psychiatry 1993;54:59–62.
Heresco-Levy U, Greenberg D, Lerer B, Dasberg H, Brown WA. Two-year trial of maintenance neuroleptic dose reduction in schizophrenic out-patients: predictors of relapse. Isr J Psychiatry Relat Sci 1995;32:268–75.
Hogarty GE, Ulrich RF, Mussare F, Aristigueta N. Drug discontinuation among long term, successfully maintained schizophrenic outpatients. Dis Nerv Syst 1976;37:494–500.
Inada T, Beasley CM, JR, Tanaka Y, Walker DJ. Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol. Int Clin Psychopharmacol 2003;18:39–48.
Inderbitzin LB, Lewine RRJ, SchellerGilkey G, Swofford CD, Egan GJ, Gloersen BA, et al. A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients. Am J Psychiatry 1994;151:1753–9.
Ingram NA, Newgreen DB. The use of tacrine for tardive dyskinesia. Am J Psychiatry 1983;140:1629–31.
Izumi K, Tominaga H, Koja T, Nomoto M, Shimizu T, Sonoda H, et al. Meclofenoxate therapy in tardive dyskinesia: a preliminary report. Biol Psychiatry 1986;21:151–60.
Jeste DV, Olgiati SG, Ghali AY. Masking of tardive dyskinesia with four times-a-day administration of chlorpromazine. Dis Nerv Syst 1977;38:755–8.
Jeste DV, Potkin SG, Sinha S, Feder S, Wyatt RJ. Tardive dyskinesia – reversible and persistent. Arch Gen Psychiatry 1979;36:585–90.
Johnson DAW, Pasterski G, Ludlow JM, Street K, Taylor RDW. The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatr Scand 1983;67:339–52.
Jus K, Jus A, Gautier J, Villeneuve A, Pires P, Pineau R, Villeneuve R. Studies on the action of certain pharmacological agents on tardive dykinesia and on the rabbit syndrome. Int J Clin Pharmacol 1974;9:138–45.
Jus A, Jus K, Fontaine P. Long term treatment of tardive dyskinesia. J Clin Psychiatry 1979;40:72–7.
Kalachnik JE, Harder SR, Kidd-Nielsen P, Errickson E, Doebler M, Sprague RL. Persistent tardive dyskinesia in randomly assigned neuroleptic reduction, neuroleptic nonreduction, and no-neuroleptic history groups: preliminary results. Psychopharmacol Bull 1984;20:27–32.
Kane JM, Woerner MG, Pollack S, Safferman AZ, Lieberman JA. Does clozapine cause tardive dyskinesia? J Clin Psychiatry 1993;54:327–30.
Kazamatsuri H, Chien C, Cole JO. Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine. Arch Gen Psychiatry 1972;27:95–9.
Kinon BJ, Jeste DV, Kollack-Walker S, Stauffer V, Liu-Seifert H. Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:985–96.
Kinon BJ, Stauffer VL, Wang L, Thi K, Niewoehner J, Kollack-Walker S. Olanzapine Improves Dyskinesia in Patients with Schizophrenia. International Congress on Schizophrenia Research, Colorado Springs, CO, USA, 29 March–2 April 2003.
Kinon B, Stauffer VL, Wang L, Thi KT, Kollack-Walker S. Olanzapine improves tardive dyskinesia in patients with schizophrenia in a controlled prospective study. Int J Neuropsychopharmacol 2002;5(Suppl. 1):165.
Kinon BJ, Stauffer VL, Wang L, Thi KT. Olanzapine improves tardive dyskinesia in patients with schizophrenia. Schizophren Res 2002;53(Suppl. 1):191.
Kinon BJ, Stauffer VL, Wang L, Thi KT. Olanzapine Improves Tardive Dyskinesia in Patients with Schizophrenia. 155th Annual Meeting of the American Psychiatric Association, Philadelphia, PA, USA, 18–23 May 2002.
Kirch D, Hattox S, Bell J, Murphy R, Freedman R. Plasma homovanillic acid and tardive dyskinesia during neuroleptic maintenance and withdrawal. Psychiatry Res 1983;9:217–23.
Klawans HL, Rubovits R. Effect of cholinergic and anticholinergic agents on tardive dyskinesia. J Neurol Neurosurg Psychiatr 1974;37:941–7.
Kollack-Walker S, Kinon BJ, Stauffer VL, Wang L, Thi KT. Olanzapine improves tardive dyskinesia in patients with schizophrenia. Schizophren Res 2003;60:359.
König P, Chwatal K, Havelec L, Riedl F, Schubert H, Schultes H. Amantadine versus biperiden: a double-blind study of treatment efficacy in neuroleptic extrapyramidal movement disorders. Neuropsychobiology 1996;33:80–4.
Korsgaard S, Casey DE, Damgaard Pedersen NE, Jørgensen A, Gerlach J. Vasopressin in anergic schizophrenia. A cross-over study with lysine-8-vasopressin and placebo. Psychopharmacology 1981;74:379–82.
Korsgaard S, Casey DE, Gerlach J, Hetmar O, Kaldan B, Mikkelsen LB. The effect of tetrahydroisoxazolopyridinol (THIP) in tardive dyskinesia: a new gamma-aminobutyric acid agonist. Arch Gen Psychiatry 1982;39:1017–21.
Korsgaard S, Casey DE, Gerlach J. Effect of gamma-vinyl GABA in tardive dyskinesia. Psychiatry Res 1983;8:261–9.
Korsgaard S, Casey D, Gerlach J. GABA Agonist Treatment of Tardive Dyskinesia. Proceedings of the 13th Congress of Collegium Internationale Neuropsychopharmacologicum, Jerusalem, Israel, 20–25 June 1982.
Kumar BB. Treatment of tardive dyskinesia with deanol. Am J Psychiatry 1976;133:978.
Lambert PA, Cantiniaux P, Chabannes JP, Tell GP, Schechter PJ, Koch-Weser J. [Therapeutic trial of gamma-vinyl GABA, an inhibitor of GABA transaminase, in tardive dyskinesias induced by neuroleptics.] Encephale 1982;8:371–6.
Laterre EC, Fortemps E. Letter: Deanol in spontaneous and induced dyskinesias. Lancet 1975;1:1301.
Leblanc G, Cormier H, Gagné MA, Vaillancourt S. Effects of neuroleptic reduction in schizophrenic outpatients receiving high doses. Can J Psychiatry 1994;39:223–9.
Leblhuber F. Treatment of permanent tardive dyskinesia with tiapride, a selective D2-receptor blocking agent. Clin Neuropharmacol 1987;10:458–61.
Lejoyeux M, Gorwood P, Stalla-Bourdillon A, Adès J. [Translation and application of the Simpson and Angus Scale of Extrapyramidal Symptoms.] Encephale 1993;19:17–21.
Levy MI, Davis BM, Mohs RC, Kendler KS, Mathé AA, Trigos G, et al. Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses. Arch Gen Psychiatry 1984;41:520–4.
Lieberman JA, Saltz BL, Johns CA, Pollack S, Kane JM. Clozapine effects on tardive dyskinesia. Psychopharmacol Bull 1989;25:57–62.
Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991;158:503–10.
Lin CC, Chen JY, Bai YM, Chen TT, Wang YC, Liou YJ, Lin WK. Remission of tardive dyskinesia following the switch from clozapine to zotepine: 2-year follow-up. Eur Neuropsychopharmacol 2006;16(Suppl. 4):410.
Littrell K, Magill AM. The effect of clozapine on preexisting tardive dyskinesia. J Psychosoc Nurs Ment Health Serv 1993;31:14–18.
Lonowski DJ, Sterling FE, King HA. Electromyographic assessment of dimethylaminoethanol (deanol) in treatment of tardive dyskinesia. Psychol Rep 1979;45:415–19.
MacKay AV, Sheppard GP, Saha BK, Motley B, Johnson AL, Marsden CD. Failure of lithium treatment in established tardive dyskinesia. Psychol Med 1980;10:583–7.
Marsalek M, Filip V, Praskova H, Karen P. An open trial with 7-methoxytacrine in tardive dyskinesia. Eur Neuropsychopharmacol 1994;4:369.
Meco G, Bedini L, Bonifati V, Sonsini U. Risperidone in the treatment of chronic schizophrenia with tardive dyskinesia. A single-blind crossover study versus placebo. Curr Therap Res 1989;46:876–83.
Mehta D, Mehta S, Mathew P. Failure of deanol in treating tardive dyskinesia. Am J Psychiatry 1976;133:1467.
Miller DD, Flaum M, Arndt S, Fleming F, Andreasen NC. Effect of antipsychotic withdrawal on negative symptoms in schizophrenia. Neuropsychopharmacology 1994;11:11–20.
Monteleone P, Maj M, Ariano MG, Iovino M, Fiorenza L, Steardo L. Prolactin response to sodium valproate in schizophrenics with and without tardive dyskinesia. Psychopharmacology 1988;96:223–6.
Moore DC, Bowers MB. Identification of a subgroup of tardive dyskinesia patients by pharmacologic probes. Am J Psychiatry 1980;137:1202–5.
Morselli PL, Fournier V, Bossi L, Musch B. Clinical activity of GABA agonists in neuroleptic- and L-dopa-induced dyskinesia. Psychopharmacology Suppl 1985;2:128–36.
Nagao T, Ohshimo T, Mitsunobu K, Sato M, Otsuki S. Cerebrospinal fluid monoamine metabolites and cyclic nucleotides in chronic schizophrenic patients with tardive dyskinesia or drug-induced tremor. Biol Psychiatry 1979;14:509–23.
Nasrallah HA, Dunner FJ, Smith RE, McCalley-Whitters M, Sherman AD. Variable clinical response to choline in tardive dyskinesia. Psychol Med 1984;14:697–700.
Nasrallah HA, Dunner FJ, McCalley-Whitters M. A placebo-controlled trial of valproate in tardive dyskinesia. Biol Psychiatry 1985;20:205–8.
Nechifor M, Vaideanu C, Palamaru I, Borza C, Mindreci I. The influence of some antipsychotics on erythrocyte magnesium and plasma magnesium, calcium, copper and zinc in patients with paranoid schizophrenia. J Am Coll Nutr 2004;23:549S–51S.
Noring U, Povlsen UJ, Casey DE, Gerlach J. Effect of a cholinomimetic drug (RS 86) in tardive dyskinesia and drug-related parkinsonism. Psychopharmacology 1984;84:569–71.
Pai YM, Yu SC, Lin CC. Risperidone in Reducing Tardive Dyskinesia: A Double-Blind, Placebo-Controlled Study. Annual Meeting of the American Psychiatric Association, New Orleans, LA, USA, 5–10 May 2001.
Pai Y-M, Yu S-C, Lin C-C. Risperidone in Reducing Tardive Dyskinesia: A Double-Blind, Placebo-Controlled Study. 155th Annual Meeting of the American Psychiatric Association, Philadelphia, PA, USA, 18–23 May 2002.
Paulson GW, Rizvi CA, Crane GE. Tardive dyskinesia as a possible sequel of long-term therapy with phenothiazines. Clin Pediatr 1975;14:953–5.
Peacock L, Solgaard T, Lublin H, Gerlach J. Clozapine versus typical antipsychotics. A retro- and prospective study of extrapyramidal side effects. Psychopharmacology 1996;124:188–96.
Peet M, Laugharne J, Rangarajan N, Reynolds GP. Tardive dyskinesia, lipid peroxidation and sustained amelioration with vitamin E treatment. Int Clin Psychopharmacol 1993;8:151–3.
Peet M, Laugharne J, Rangarajan N, Reynolds G. Tardive dyskinesia. Hosp Community Psychiatry 1993;44:795.
Prange A, Wilson JC, Morris CE, Hall CD. Preliminary experience with tryptophan and lithium in the treatment of tardive dyskinesia. Psychopharmacol Bull 1973;9:36–7.
Price WA, Pascarzi GA. Use of verapamil to treat negative symptoms in schizophrenia. J Clin Psychopharmacol 1987;7:357.
Pyke J, Seeman MV. Neuroleptic-free intervals in the treatment of schizophrenia. Am J Psychiatry 1981;138:1620–1.
Quitkin F, Rifkin A, Gochfeld L, Klein DF. Tardive dyskinesia: are first signs reversible? Am J Psychiatry 1977;134:84–7.
Rapoport J, Kumra S, Jacobsen LK. The Spectrum of Extrapyramidal Symptoms in Children and Young Adults. 150th Annual Meeting of the American Psychiatric Association, San Diego, CA, USA, 17–22 May 1997.
Ray R, Ramakrishnan N, Rao BS. Oral choline in tardive dyskinesia. Indian J Med Res 1982;76:628–31.
Reda FA, Scanlan JM, Kemp K, Escobar JI. Letter: Treatment of tardive dyskinesia with lithium carbonate. N Engl J Med 1974;291:850.
Reda FA, Escobar JI, Scanlan JM. Lithium carbonate in the treatment of tardive dyskinesia. Am J Psychiatry 1975;132:560–2.
Reker D, Anderson B, Yackulic C, Cooper TB, Banay-Schwartz M, Leon C, Volavka J. Naloxone, tardive dyskinesia, and endogenous beta-endorphin. Psychiatry Res 1982;7:321–4.
Volavka J, Anderson B, Koz G. Naloxone and naltrexone in mental illness and tardive dyskinesia. Ann N Y Acad Sci 1982;398:97–102.
Rektor J. [The cholinergic system in the pathophysiology of tardive dyskinesia.] Cesk Psychiatr 1988;84:289–96.
Ringwald E. [Dopamine-receptor stimulators and neuroleptic-induced dyskinesia (author’s transl).] Pharmakopsychiatr Neuropsychopharmakol 1978;11:294–8.
Rondot P, Bathien N. Movement disorders in patients with coexistent neuroleptic-induced tremor and tardive dyskinesia: EMG and pharmacological study. Adv Neurol 1987;45:361–6.
Bathien N, Sevestre P, Rondot P, Morselli PL, Van Landeghem V. The Effect of Progabide, a Specific GABAergic Agonist, on Neuroleptic-Induced Tardive Dyskinesia – A Result of a Pilot Study. Proceedings of the 13th Collegium Internationale Neuropsychopharmacologicum Congress, Jerusalem, Israel, 20–25 June 1982.
Ross JL, Mackenzie TB, Hanson DR, Charles CR. Diltiazem for tardive dyskinesia. Lancet 1987;1:268.
Roxburgh PA. Treatment of persistent phenothiazine-induced oral dyskinesia. Br J Psychiatry 1970;116:277–80.
Sarbulescu A, Alexandrescu L, Georgescu M. Comparative study of two benzodiazepines (‘diazepam’ versus ‘nitrazepam’) in the treatment of postneuroleptic tardive dyskinesia. Rev Roum Neurol Psychiatr 1986;24:189–93.
Schultz SK, Miller DD, Arndt S, Ziebell S, Gupta S, Andreasen NC. Withdrawal-emergent dyskinesia in patients with schizophrenia during antipsychotic discontinuation. Biol Psychiatry 1995;38:713–19.
Seeman MV. Tardive dyskinesia: two-year recovery. Compr Psychiatry 1981;22:189–92.
Simpson GM, Branchey MH, Lee JH, Voitashevsky A, Zoubok B. Lithium in tardive dyskinesia. Pharmakopsychiatr Neuropsychopharmakol 1976;9:76–80.
Simpson GM, Zoubok B, Lee JH. An early clinical and toxicity trial of EX 11-582A in chronic schizophrenia. Curr Ther Res Clin Exp 1976;19:87–98.
Simpson GM, Lee JH, Shrivastava RK, Branchey MH. Baclofen in the treatment of tardive dyskinesia and schizophrenia. Psychopharmacol Bull 1978;14:16–18.
Simpson GM, Lee JH, Shrivastava RK. Clozapine in tardive dyskinesia. Psychopharmacology 1978;56:75–80.
Singh MM, Nasrallah HA, Lal H, Pitman RK, Becker RE, Kucharski T, et al. Treatment of tardive dyskinesia with diazepam: indirect evidence for the involvement of limbic, possibly GABA-ergic mechanisms. Brain Res Bull 1980;5(Suppl. 2):673–80.
Singh MM, Becker RE, Pitman RK, Nasrallah HA, Lal H, Dufresne RL, et al. Diazepam-induced changes in tardive dyskinesia: suggestions for a new conceptual model. Biol Psychiatry 1982;17:729–42.
Singh MM, Becker RE, Pitman RK, Nasrallah HA, Lal H. Sustained improvement in tardive dyskinesia with diazepam: indirect evidence for corticolimbic involvement. Brain Res Bull 1983;11:179–85.
Small JG, Milstein V, Marhenke JD, Hall DD, Kellams JJ. Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis. J Clin Psychiatry 1987;48:263–7.
Smith RC, Tamminga CA, Haraszti J, Pandey GN, Davis JM. Effects of dopamine agonists in tardive dyskinesia. Am J Psychiatry 1977;134:763–8.
Smith JS, Kiloh LG. Six month evaluation of thiopropazate hydrochloride in tardive dyskinesia. J Neurol Neurosurg Psychiatr 1979;42:576–9.
Soni SD, Freeman HL, Hussein EM. Oxypertine in tardive dyskinesia: an 8-week controlled study. Br J Psychiatry 1984;144:48–52.
Spivak B, Schwartz B, Radwan M, Weizman A. alpha-Tocopherol treatment for tardive dyskinesia. J Nerv Ment Dis 1992;180:400–1.
Spivak B, Mester R, Abesgaus J, Wittenberg N, Adlersberg S, Gonen N, Weizman A. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. J Clin Psychiatry 1997;58:318–22.
Stahl SM, Thornton JE, Simpson ML, Berger PA, Napoliello MJ. Gamma-vinyl-GABA treatment of tardive dyskinesia and other movement disorders. Biol Psychiatry 1985;20:888–93.
Tamminga CA, Smith RC, Ericksen SE, Chang S, Davis JM. Cholinergic influences in tardive dyskinesia. Am J Psychiatry 1977;134:769–74.
Tell GP, Schechter PJ, Koch-Weser J, Cantiniaux P, Chabannes JP, Lambert PA. Effects of gamma-vinyl GABA. N Engl J Med 1981;305:581–2.
Turek I, Kurland AA, Hanlon TE, Bohm M. Tardive dyskinesia: its relation to neuroleptic and antiparkinson drugs. Br J Psychiatry 1972;121:605–12.
Villeneuve A, Böszörményi Z. Treatment of drug-induced dyskinesias. Lancet 1970;1:353–4.
Villeneuve A, Cazejust T, Côté M. Estrogens in tardive dyskinesia in male psychiatric patients. Neuropsychobiology 1980;6:145–51.
Volavka J, O’Donnell J, Muragali R, Anderson BG, Gaztanaga P, Boggiano W, et al. Lithium and lecithin in tardive dyskinesia: an update. Psychiatry Res 1986;19:101–4.
Wang D, Xie F, Gao Z. Persistent tardive dyskinesia treated with clonazepam. Chin J Pharmacoepidemiol 2002;11:284–6.
Wirshing WC, Freidenberg DL, Cummings JL, Bartzokis G. Effect of anticholinergic agents on patients with tardive dyskinesia and concomitant drug-induced parkinsonism. J Clin Psychopharmacol 1989;9:407–11.
Wolf MA, Bailly L, Diener JM, Martinet JP, Peretti S, Garneau Y. Sevrage neuroleptique complet chez des patients schizophrenes presentant une symptomatologie intense et resistant au traitement. Encephale 1991;17:255–61.
Wright P, Tollefson GD, Beasley CM, Tamura RN, Tran PV, Potvin JII. A blinded, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Schizophren Res 1998;29:206.
Zander KJ, Fischer B, Zimmer R, Ackenheil M. Long-term neuroleptic treatment of chronic schizophrenic patients: clinical and biochemical effects of withdrawal. Psychopharmacology 1981;73:43–7.
Zapletálek M, Hanus H, Fusek J, Hrdina V. First experience with the application of 7-methoxytacrine to psychiatric patients. Act Nerv Super 1989;31:305–6.
Zarebinski JM, Royds JN. Sulpiride in tardive dyskinesia. S Afr Med J 1990;78:374–5.
Zwanikken GJ, Oei TT, Kimya S, Amery W. Safety and efficacy of prolonged treatment with Tremblex (dexetimide), an antiparkinsonian agent. A controlled study. Acta Psychiatr Belg 1976;76:467–9.
Randomised but not tardive dyskinesia
Adler LA, Angrist B, Rotrosen J. Metoprolol versus propranolol. Biol Psychiatry 1990;27:673–5.
Apseloff G, Mullet D, Wilner KD, Anziano RJ, Tensfeldt TG, Pelletier SM, Gerber N. The effects of ziprasidone on steady-state lithium levels and renal clearance of lithium. Br J Clin Pharmacol 2000;49(Suppl. 1):61–4.
Barnes T. A Prospective Study of Tardive Dyskinesia in the Elderly; Single-Blind Comparison of Amisulpride and Risperidone. Leeds: National Research Register; 2002.
Bisol LW, Brunstein MG, Ottoni GL, Ramos FLP, Borba DL, Daltio CS, et al. Is flunarizine a long-acting oral atypical antipsychotic? A randomized clinical trial versus haloperidol for the treatment of schizophrenia. J Clin Psychiatry 2008;69:1572–9.
Bitter I, Slabber M, Pretorius J, Bartko GY, Danics Z, Dossenbach M, et al. Olanzapine versus clozapine in patients non responsive or intolerant to standard acceptable treatment of schizophrenia. Int J Neuropsychopharmacol 2000;3(Suppl. 1):141.
Brecher M, Okamoto A, Napolitano J, Kane JM, Risperidone Study Group. Low frequency of tardive dyskinesia in elderly patients with dementia exposed to risperidone for up to one year. Am J Geriatr Psychiatry 1999;7:53–4.
Brecher M, Okamoto A, Napolitano J, Kane JM, The Risperidone Study Group. Low frequency of tardive dyskinesia in elderly patients with dementia exposed to risperidone for up to one year. Schizophren Res 1999;1–3:362.
Brecher M. Follow-up Study of Risperidone in the Treatment of Patients with Dementia: Interim Results on Tardive Dyskinesia and Dyskinesia Severity. Proceedings of the 11th European College of Neuropsychopharmacology Congress, Paris, France, 31 October–4 November 1998.
Caine ED, Polinsky RJ, Kartzinel R, Ebert MH. The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry 1979;136:317–20.
Carman JS, Wyatt RJ. Calcium: pacesetting the periodic psychoses. Am J Psychiatry 1979;136:1035–9.
Chaplin R, Timehin C. Informing patients about tardive dyskinesia: four-year follow up of a trial of patient education. Aust N Z J Psychiatry 2002;36:99–103.
Chaplin R, Zipursky RB. An educational session on tardive dyskinesia increased patients’ knowledge at 6 months without affecting compliance or clinical stability. Evidence-Based Med 1998;3:153.
Chaplin R, Kent A. Informing patients about tardive dyskinesia. Controlled trial of patient education. Br J Psychiatry 1998;172:78–81.
Chiu SS. A Placebo-Controlled Cross Study of Panax ginseng in Augmentation of Antipsychotics in 60 Partially Treatment Responsive Patients with Schizophrenia. 2006. URL: https://clinicaltrials.gov/ct2/show/NCT00401089 (accessed 6 June 2017).
Chouinard G, Annable L, Kropsky M. A double-blind controlled study of pipothiazine palmitate in the maintenance treatment of schizophrenic outpatients. J Clin Pharmacol 1978;18:148–54.
Chouinard G, Annable L, Ross-Chouinard A, Kropsky ML. Ethopropazine and benztropine in neuroleptic-induced parkinsonism. J Clin Psychiatry 1979;40:147–52.
Chouinard G, Annable L, Campbell W. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia. J Clin Psychopharmacol 1989;9:247–53.
Chouinard G, Vainer JL, Belanger MC, Turnier L, Beaudry P, Roy JY, et al. Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis. Progr Neuropsychopharmacol Biol Psychiatry 1994;18:1129–41.
Cookson JC. Side effects during long-term treatment with depot antipsychotic medication. Clin Neuropharmacol 1991;14(Suppl. 2):24–30.
Cortese L, Caligiuri MP, Williams R, Schieldrop P, Manchanda R, Malla A, et al. Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia. J Clin Psychopharmacol 2008;28:69–73.
Crane GE. High doses of trifluperazine and tardive dyskinesia. Arch Neurol 1970;22:176–80.
Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC. Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial. II. The incidence of compliance problems, side-effects, neurotic symptoms and depression. Br J Psychiatry 1985;146:469–74.
Davidson M, Harvey PD, Vervarcke J, Gagiano CA, De Hooge JD, Bray G, et al. A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group. Int J Geriatr Psychiatry 2000;15:506–14.
DiMascio A, Bernardo DL, Greenblatt DJ, Marder JE. A controlled trial of amantadine in drug-induced extrapyramidal disorders. Arch Gen Psychiatry 1976;33:599–602.
DiMascio A, Bernardo DL, Greenblatt DJ, Marder JE. A controlled trial of amantadine in drug-induced extrapyramidal disorders. Psychopharmacol Bull 1977;13:31–3.
Dorfman-Etrog P, Hermesh H, Prilipko L, Weizman A, Munitz H. The effect of vitamin E addition to acute neuroleptic treatment on the emergence of extrapyramidal side effects in schizophrenic patients: an open label study. Eur Neuropsychopharmacol 1999;9:475–7.
Dose M. [The significance of calcium antagonists and anticonvulsants for the pharmacotherapy of psychoses.] Habilitationsschrift der Technischen Universitat Munchen 1991;1991:11–48.
Double DB, Warren GC, Evans M, Rowlands RP. Efficacy of maintenance use of anticholinergic agents. Acta Psychiatr Scand 1993;88:381–4.
Egan MF, Zhao X, Smith A, Troyer MD, Uebele VN, Pidkorytov V, et al. Randomized controlled study of the T-type calcium channel antagonist MK-8998 for the treatment of acute psychosis in patients with schizophrenia. Hum Psychopharmacol 2013;28:124–33.
Ehrenreich H, Hinze-Selch D, Stawicki S, Aust C, Knolle-Veentjer S, Wilms S, et al. Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol Psychiatry 2007;12:206–20.
Elie R, Morin L, Tétreault L. [Effects of ethopropazine and trihexyphenidyl on several parameters of the neuroleptic syndrome.] Encephale 1972;61:32–52.
Emsley R, Myburgh C, Oosthuizen P, van Rensburg SJ. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry 2002;159:1596–8.
Fann WE, Lake CR. Amantadine versus trihexyphenidyl in the treatment of neuroleptic-induced parkinsonism. Am J Psychiatry 1976;133:940–3.
Fay-McCarthy M, Kendrick KA, Rosse RB, Schwartz BL, Peace T, Wyatt RJ, Deutsch SI. The effect of nifedipine on akathisia and agitation in patients with movement disorders. Schizophren Res 1997;24:208.
Fay-McCarthy M, Kendrick KA, Rosse RB, Schwartz BL, Peace T, Wyatt RJ, Deutsch SI. The effect of nifedipine on tardive dyskinesia: a double blind study in eighteen patients. Schizophren Res 1997;24:271.
Gerlach J, Thorsen K, Fog R. Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients. Psychopharmacology 1975;40:341–50.
Goetz CG, Stebbins GT, Chung KA, Hauser RA, Miyasaki JM, Nicholas AP, et al. No PD dyskinesia scale protects against placebo responses: a comparison of seven scales. Move Disord 2013;28:S115–16.
Goetz C, Stebbins G, Chung K, Hauser R, Miyasaki J, Nicholas A, et al. No PD dyskinesia scale protects against placebo responses: a comparison of multiple scales. Neurology 2013;80(Suppl. 7):P04.187.
Goldberg SC, Shenoy RS, Sadler A, Hamer R, Ross B. The effects of a drug holiday on relapse and tardive dyskinesia in chronic schizophrenics [proceedings.] Psychopharmacol Bull 1981;17:116–17.
Gulmann NC, Bahr B, Andersen B, Eliassen HM. A double-blind trial of baclofen against placebo in the treatment of schizophrenia. Acta Psychiatr Scand 1976;54:287–93.
Gutierrez M, Alpert M, Guimon J, Friedhoff AJ, Veramendi V. [Controlled study on the possibilities of L-dopa in the residual extrapyramidal syndrome caused by neuroleptics.] Actas Esp Psiquiatr 1979;7:181–8.
Hershon HI, Kennedy PF, McGuire RJ. Persistence of extra-pyramidal disorders and psychiatric relapse after withdrawal of long-term phenothiazine therapy. Br J Psychiatry 1972;120:41–50.
Hogarty GE, McEvoy JP, Munetz M, DiBarry AL, Bartone P, Cather R, et al. Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia – results of a two-year controlled study. Arch Gen Psychiatry 1988;45:797–805.
Huang J-L, Fu Z-C, Sun Q-Q. Trilafon in combination with nimodipine in the treatment of 30 senile patients with first-episode schizophrenia. Herald Med 2004;23:152–3.
Janicak PG, Sharma RP, Pandey G, Davis JM. Verapamil for the treatment of acute mania: a double-blind, placebo-controlled trial. Am J Psychiatry 1998;155:972–3.
Jean-Noel B, Wood AJ, Kiesler GM, Birkett M, Tollefson GD. Olanzapine vs. Clozapine: an International Double Blind Study in the Treatment of Resistant Schizophrenia. Proceedings of the 11th World Congress of Psychiatry, Hamburg, Germany, 6–11 August 1999.
Jolley AG, Hirsch SR, McRink A, Manchanda R. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year. BMJ 1989;298:985–90.
Jolley AG, Hirsch SR, Morrison E, McRink A, Wilson L. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ 1990;301:837–42.
Kopala L, Rabinowitz J, Emsley R, Mcgorry P. Extra-pyramidal signs and symptoms (EPS) in recent onset schizophrenia: a comparison of risperidone and haloperidol. Schizophren Res 2004;67:187.
Krupitsky E, Burakov A, Romanova T, Vegso S, Krystal J. Nimodipine attenuates psychotigenic effects of ketamine in humans. Eur Neuropsychopharmacol 1999;9:S347.
Lara D. Flunarizine for Schizophrenia. Muscatine, IA: Stanley Foundation Research Programs; 2009.
Levine J, Schooler NR, Severe J, Escobar J, Gelenberg A, Mandel M, et al. Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study. Adv Biochem Psychopharmacol 1980;24:483–93.
Lieberman JA, Kane JM, Sarantakos S, Gadaleta D, Woerner M, Alvir J, Ramos-Lorenzi J. Prediction of relapse in schizophrenia. Arch Gen Psychiatry 1987;44:597–603.
Lieberman JA, Alvir J, Geisler S, Ramos-Lorenzi J, Woerner M, Novacenko H, et al. Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia. Neuropsychopharmacology 1994;11:107–18.
Liebman HM, Woo W. The addition of tiagabine to antipsychotic medication in the treatment of recent-onset schizophrenia by modification of developmental pruning of prefrontal circuitry. Schizophren Res 2010;117:380–1.
Marder SR, Van Putten T, Mintz J, Lebell M, McKenzie J, May PR. Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome. Arch Gen Psychiatry 1987;44:518–21.
Marder SR, Van Putten T, Mintz J, McKenzie J, Lebell M, Faltico G, May PR. Costs and benefits of two doses of fluphenazine. Arch Gen Psychiatry 1984;41:1025–9.
McCreadie RG, Dingwall JM, Wiles DH, Heykants JJ. Intermittent pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia. Br J Psychiatry 1980;137:510–17.
NCT00310661. A Dual-Centre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Determine the Effects of Various Adjunctive Doses of Sarizotan in the Treatment of Patients with neuroleptic-Induced Tardive Dyskinesia. 2006. URL: https://clinicaltrials.gov/ct2/show/NCT00310661 (accessed 29 May 2016).
NCT00425815. A Placebo-Controlled Trial of org 24448 (Ampakine) Added to Atypical Antipsychotics in Patients with Schizophrenia. 2007. URL: https://clinicaltrials.gov/ct2/show/NCT00425815?term=NCT00425815&rank=1 (accessed 6 June 2017).
NCT00469664. A Double Blind Placebo Controlled Study of Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia. 2007. URL: https://clinicaltrials.gov/ct2/show/NCT00469664 (accessed 6 June 2017).
NCT00512070. Melatonin Metabolism Abnormality in Patients with Schizophrenia or Schizoaffective Disorder Treated with Olanzapine and Melatonin Dose Finding for the Correction of the Metabolic Abnormality. 2007. URL: https://clinicaltrials.gov/ct2/show/NCT00512070?term=NCT00512070&rank=1 (accessed 6 June 2017).
NCT00845000. Acute Effects of SCH 420814 on Dyskinesia and Parkinsonism in Levodopa Treated Patients. 2009. URL: https://clinicaltrials.gov/ct2/show/NCT00845000?term=NCT00845000&rank=1 (accessed 29 May 2016).
Newcomer JW, Riney SJ, Vinogradov S, Csernansky JG. Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements after neuroleptic dose decrease. Psychopharmacol Bull 1992;28:101–7.
Newton JE, Cannon DJ, Couch L, Fody EP, McMillan DE, Metzer WS, et al. Effects of repeated drug holidays on serum haloperidol concentrations, psychiatric symptoms, and movement disorders in schizophrenic patients. J Clin Psychiatry 1989;50:132–5.
Odejide OA, Aderounmu AF. Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients. J Clin Psychiatry 1982;43:195–6.
O’Suilleabhain P, Dewey RB. A randomized trial of amantadine in Huntington disease. Arch Neurol 2003;60:996–8.
Peluso MJ, Lewis SW, Barnes TR, Jones PB. Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. Br J Psychiatry 2012;200:387–92.
Perry R, Campbell M, Green WH, Small AM, Die Trill ML, Meiselas K, et al. Neuroleptic-related dyskinesias in autistic children: a prospective study. Psychopharmacol Bull 1985;21:140–3.
Perry R, Campbell M, Adams P, Lynch N, Spencer EK, Curren EL, Overall JE. Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration. J Am Acad Child Adolesc Psychiatry 1989;28:87–92.
Petit P, Bottai T, Pujalte D, Hue B, Blayac JP, Pouget J. Clonazepam in neuroleptic-induced akathisia: efficacy and dose-response relationship. Fundamental Clin Pharmacol 1994;8:287.
Pickar D, Wolkowitz OM, Doran AR, Labarca R, Roy A, Breier A, Narang PK. Clinical and biochemical effects of verapamil administration to schizophrenic patients. Arch Gen Psychiatry 1987;44:113–18.
Popov MIu. [The use of nifedipine as a corrector of extrapyramidal side-effects of classical neuroleptics.] Zh Nevrol Psikhiatr Im S S Korsakova 2008;108:28–33.
Price W, Giannini AJ, Loiselle R. Antischizophrenia effects of verapamil. Int J Neurosci 1986;31:577–8.
Price WA. Antipsychotic effects of verapamil in schizophrenia. Hillside J Clin Psychiatry 1987;9:225–30.
Raptis C, Garcia-Borreguero D, Weber MM, Dose M, Bremer D, Emrich HM. Anticonvulsants as adjuncts for the neuroleptic treatment of schizophrenic psychoses: a clinical study with beclamide. Acta Psychiatr Scand 1990;81:162–7.
Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003;290:2693–702.
Sachdev P, Loneragan C. Intravenous benztropine and propranolol challenges in tardive akathisia. Psychopharmacology 1993;113:119–22.
Salmasi FB, Jazayeri M, Ghaeli P, Hashemian F, Akhondzadeh S, Raisi F, et al. Comparing the effects of high-dose vitamin E with those of placebo on insulin resistance in patients with schizophrenia treated with olanzapine. J Clin Psychopharmacol 2009;29:182–3.
Shah BB, Connolly B, Mestre TA, Prashanth LK, Miyasaki JM, Steeves T, et al.
Famotidine for the Treatment of Levodopa-Induced Dyskinesia: An Ongoing ‘N-of-1’ Study. 26th Annual Symposium on Etiology, Pathogenesis and Treatment of Movement Disorders, Irving, TX, USA, 11 May 2012.
Shenoy RS, Sadler AG, Goldberg SC, Hamer RM, Ross B. Effects of a six-week drug holiday on symptom status, relapse, and tardive dyskinesia in chronic schizophrenics. J Clin Psychopharmacol 1981;1:141–5.
Sikich L, Williamson K, Malekpour A, Bashford RA, Hooper S, Sheitman B, Lieberman JA. Interim Results of a Randomized Controlled Trial of Haloperidol, Risperidone, and Olanzapine in Psychotic Youth. Proceedings of the 38th Annual Meeting of the American College of Neuropsychopharmacology, Acapulco, Mexico, 12–16 December 1999.
Sikich L, Horrigan JP, Lieberman JA, Barnhill LJ, Sheitman BB, Courvoisie HE. Comparative Use of Olanzapine and Risperidone in Psychotic Youth. Proceedings of the 154th Annual Meeting of the American Psychiatric Association, New Orleans, LA, USA, 5–10 May 2001.
Sikich L. Critical Decisions in the Treatment of Adolescent and Pediatric Psychosis. Proceedings of the 154th Annual Meeting of the American Psychiatric Association, New Orleans, LA, USA, 5–10 May 2001.
Sikich L. Critical Decisions in the Treatment of Adolescent and Pediatric Psychosis. Proceedings of the 155th Annual Meeting of the American Psychiatric Association, Philadelphia, PA, USA, 18–23 May 2002.
Singh H, Hunt JI, Vitiello B, Simpson GM. Neuroleptic withdrawal in patients meeting criteria for supersensitivity psychosis. J Clin Psychiatry 1990;51:319–21.
Speller JC, Barnes TRE, Curson DA, Pantelis C, Alberts JL. One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol. Br J Psychiatry 1997;171:564–8.
Barnes TRE, Speller JC, Curson DA, Pantelis C, Alberts JL. A one-year dose reduction study in chronic schizophrenic inpatients: amisulpride vs haloperidol. Schizophren Res 1992;6:107.
Suh GH, Son HG, Ju YS, Jcho KH, Yeon BK, Shin Y, et al. A randomized, double-blind, crossover comparison of risperidone and haloperidol in Korean dementia patients with behavioral disturbances. Am J Geriatr Psychiatry 2004;12:509–16.
Thapa PB, Meador KG, Gideon P, Fought RL, Ray WA. Effects of antipsychotic withdrawal in elderly nursing home residents. J Am Geriatr Soc 1994;42:280–6.
Tollefson GD, Beasley CM, Tamura RN, Tran PV, Potvin JH. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 1997;154:1248–54.
Tamura RN, Tollefson GD, Dellva MA, Beasley CM, Glazer WM, Morgenstern H. What is the differential risk of tardive dyskinesia with the novel antipsychotic olanzapine? Schizophren Res 1998;29:176.
Beasley CM, Dellva MA, Tamura RN, Morgenstern H, Glazer WM, Ferguson K, Tollefson GD. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999;174:23–30.
Tran PV, Dellva MA, Tollefson GD, Beasley CM, Potvin JH, Kiesler GM. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 1997;58:205–11.
Vaddadi KS, Soosai E, Chiu E, Dingjan P. A randomised, placebo-controlled, double blind study of treatment of Huntington’s disease with unsaturated fatty acids. Neuroreport 2002;13:29–33.
Wang Q, Wei X. Propranolol and verapamil therapy antipsychotics due to sinus tachycardia control study. Central Plains Med J 1995;22:26–7.
Wang F, Lu Y. The control study of clonazepam and artane in akathisia. J Clin Psychosom Dis 2000;6:19–20.
Wei X-Y, Zhu A, Li N, Chen Z. Propranolol vs verapamil in treating drug-induced sinus tachycardia. Chin J N Drugs Clin Remedies 1995;14:336–7.
Wei P. Efficacy of nimodipine combined sulpiride treatment of the negative symptoms of schizophrenia. Int Med Health Guidance News 2008;14:54–6.
Williamson DJ, Tran PV, Beasley CM, Tollefson GD, Sanger T, Satterlee WG. Clinical efficacy and safety of olanzapine, a new atypical antipsychotic agent. J Psychopharmacol 1995;9:A47.
Wirshing DA, Marshall BD, Green MF, Mintz J, Marder SR, Wirshing WC. Risperidone in treatment-refractory schizophrenia. Am J Psychiatry 1999;156:1374–9.
Wistedt B, Wiles D, Jørgensen A. A depot neuroleptic withdrawal study neurological effects. Psychopharmacology 1983;80:101–5.
Yaryura-Tobias JA, Krumholz WV, Wolpert A, White L, Merlis S. Calcium as a proposed treatment for drug-induced extrapyramidal symptoms. Psychopharmacol Bull 1968;4:36–7.
Randomised, tardive dyskinesia, but not stabilised on antipsychotics
Cassady SL, Thaker GK, Moran M, Birt A, Tamminga CA. GABA agonist-induced changes in motor, oculomotor, and attention measures correlate in schizophrenics with tardive dyskinesia. Biol Psychiatry 1992;32:302–11.
Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann Neurol 1982;11:41–7.
Lieberman JA, Alvir J, Mukherjee S, Kane JM. Treatment of tardive dyskinesia with bromocriptine. A test of the receptor modification strategy. Arch Gen Psychiatry 1989;46:908–13.
Perovich RM, Lieberman JA, Fleischhacker WW, Alvir J. The behavioral toxicity of bromocriptine in patients with psychiatric illness. J Clin Psychopharmacol 1989;9:417–22.
Simpson GM, Voitashevsky A, Young MA, Lee JH. Deanol in the treatment of tardive dyskinesia. Psychopharmacology 1977;52:257–61.
Tamminga CA, Crayton JW, Chase TN. Improvement in tardive dyskinesia after muscimol therapy. Arch Gen Psychiatry 1979;36:595–8.
Randomised, tardive dyskinesia, no usable data reported – authors contacted to confirm lack of data
Alpert M, Friedhoff AJ, Diamond F. Use of dopamine receptor agonists to reduce dopamine receptor number as treatment for tardive dyskinesia. Adv Neurol 1983;37:253–8.
Andia I, Zumarraga M, Zabalo MJ, Bulbena A, Davila R. Differential effect of haloperidol and clozapine on plasma homovanillic acid in elderly schizophrenic patients with or without tardive dyskinesia. Biol Psychiatry 1998;43:20–3.
Diehl A, Braus DF, Büchel C, Krumm B, Medori R, Gattaz WF. [Tardive dyskinesia: pergolid, a possible therapeutic option.] Psychiatr Prax 2003;30:333–7. http://dx.doi.org/10.1055/s-2003-42166
Diehl A, Dittmann RW, Gattaz W, Rubin M, Hundemer HP. Low Dose Pergolide in the Treatment of Tardive Dyskinesia (TD): A Double Blind, Placebo Controlled Randomised Cross Over Trial. 11th World Congress of Psychiatry, Hamburg, Germany, 6–11 August 1999.
Diehl A, Hundemer HP, Rubin M, Dittmann RW, Gattaz W. Low-dose pergolide in the treatment of tardive dyskinesia (TD): a double-blind, placebo-controlled randomized cross-over trial. J Eur Coll Neuropsychopharmacol 1999;9:S359.
Frangos E, Athanasenas E. Lioresal in the Treatment of Neuroleptic-Induced Tardive Dyskinesia. Proceedings of the 12th CINP Congress, Gothenburg, Sweden, 22–26 June 1980.
Fudge RC, Thailer SA, Alpert M, Intrator J, Sison CE. The effects of electromyographic feedback training on suppression of the oral-lingual movements associated with tardive dyskinesia. Biofeedb Self-Regulat 1991;16:117–29.
Herz MI, Glazer WM, Mostert MA, Sheard MA, Szymanski HV, Hafez H, et al. Intermittent vs maintenance medication in schizophrenia. Two-year results. Arch Gen Psychiatry 1991;48:333–9.
Johnson DA, Ludlow JM, Street K, Taylor RD. Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia. Br J Psychiatry 1987;151:634–8.
Junker D, Steigleider P, Gattaz WF. Alpha-tocopherol in the treatment of tardive dyskinesia. Schizophren Res 1992;6:122–3.
Koller WC, Barr A, Biary N. Estrogen treatment of dyskinetic disorders. Neurology 1982;32:547–9.
Leys D, Vermersch P, Danel T, Comayras S, Goudemand M, Caron J, Petit H. Diltiazem for tardive dyskinesia. Lancet 1988;1:250–1.
Quinn N, Marsden CD. A double blind trial of sulpiride in Huntington’s disease and tardive dyskinesia. J Neurol Neurosurg Psychiatr 1984;47:844–7.
Quinn N, Marsden, CD. [Double blind trial of dogmatil in Huntington chorea and tardive dyskinesia.] Sem Hop1985;61:1376–80.
Sommer BR, Cohen BM, Satlin A, Cole JO, Jandorf L, Dorsey F. Changes in tardive dyskinesia symptoms in elderly patients treated with ganglioside GM1 or placebo. J Geriatr Psychiatry Neurol 1994;7:234–7.
Peselow ED, Irons S, Rotrosen J, Alonso MT, Dorsey F. GM1 ganglioside as a potential treatment in tardive dyskinesia. Psychopharmacol Bull 1989;25:277–80.
Spohn HE, Coyne L, Spray J. The effect of neuroleptics and tardive dyskinesia on smooth-pursuit eye movement in chronic schizophrenics. Arch Gen Psychiatry 1988;45:833–40.
Spohn HE, Coyne L. The effect of attention/information processing impairment of tardive dyskinesia and neuroleptics in chronic schizophrenics. Special Issue: Tardive dyskinesia and cognitive dysfunction. Brain Cogn 1993;23:28–39.
Thaker GK, Nguyen JA, Strauss ME, Jacobson R, Kaup BA, Tamminga CA. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry 1990;147:445–51.
Randomised, tardive dyskinesia, but no usable data reported – no author contact details, study > 20 years old
Borison RL, Shah C, White TH, Diamond BI. Atypical and typical neuroleptics and tardive dyskinesia. Psychopharmacol Bull 1987;23:218–20.
Greendyke RM, Webster JC, Kim J, Kim H. Lack of efficacy of pindolol in tardive dyskinesia. Am J Psychiatry 1988;145:1318–19.
Kabes J, Sikora J, Pisvejc J, Hanzlicek L, Skondia V. Effect of piracetam on extrapyramidal side effects induced by neuroleptic drugs. Int Pharmacopsychiatry 1982;17:185–92.
Kabes J, Sikora J, Pisvejc J, Skoudia V. Piracetam Action in Neuroleptic Induced Extrapyramidal Side-Effects. In Proceedings of the 12th CINP Congress, Supplement to Progress in Neuropsychopharmacology. Oxford: Pergamon Press; 1980.
Sikora J, Kabes J, Pisvejc J. [Management of neuroleptic side-effects with piracetam (author’s translation).] Cesk Psychiatr 1981;77:137–42.
Kabes J, Sikora J, Stary O, Piisvejc J, Hanzlicek L. Piracetam effectivity in tardive dyskinesia. A double-blind placebo-controlled cross-over trial. Cesk Psychiatr 1983;79:339–45.
Kabes J, Sikora J, Stary O, Pisvejc J. Dose-dependent effect of piracetam in tardive-dyskinesia – double-blind placebo controlled trial. Activitas Nervosa Superior 1985;27:64–6.
Ludatscher JI. Stable remission of tardive dyskinesia by L-dopa. J Clin Psychopharmacol 1989;9:39–41.
Marsalek M, Filip V, Petrovsky M, Klar I, Filipova M, Klaschka J. 7-MEOTA in the treatment of tardive dyskinesia. Double-blind placebo controlled study. Homeostasis 1997;38:7.
Rzewuska M, Soucka K. Therapeutic Effect of Diltiazem in Tardive Dyskinesia. Proceedings of the 8th European College of Neuropsychopharmacology Congress, Venice, Italy, 30 September–4 October 1995.
Rzewuska M, Sobucka K. Therapeutic effect of diltiazem in tardive dyskinesia. Eur Neuropsychopharmacol 1995;5:390–1.
Sikora J, Kabes J, Pisvejc J. [Management of neuroleptic side-effects with piracetam (author’s translation).] Cesk Psychiatr 1981;77:137–42.
Randomised, tardive dyskinesia, but no separate data reported on minority with tardive dyskinesia – authors contacted to confirm lack of data
de Jesus Mari J, Lima MS, Costa AN, Alexandrino N, Rodrigues-Filho S, de Oliveira IR, Tollefson GD. The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders. Eur Arch Psychiatry Clin Neurosci 2004;254:356–61.
Klett CJ, Caffey E. Evaluating the long-term need for antiparkinson drugs by chronic schizophrenics. Arch Gen Psychiatry 1972;26:374–9.
Suddath RL, Straw GM, Freed WJ, Bigelow LB, Kirch DG, Wyatt RJ. A clinical trial of nifedipine in schizophrenia and tardive dyskinesia. Pharmacol Biochem Behav 1991;39:743–5.
Randomised, tardive dyskinesia, but crossover trial with no separate data reported for phase before crossing over to second treatment – authors contacted to confirm lack of data
Domino EF, May WW, Demetriou S, Mathews B, Tait S, Kovacic B. Lack of clinically significant improvement of patients with tardive dyskinesia following phosphatidylcholine therapy. Biol Psychiatry 1985;20:1189–96.
Doongaji DR, Jeste DV, Jape NM, Sheth AS, Apte JS, Vahia VN, et al. Effects of intravenous metoclopramide in 81 patients with tardive dyskinesia. J Clin Psychopharmacol 1982;2:376–9.
Fann WE, Davis JM, Wilson IC. Methylphenidate in tardive dyskinesia. Am J Psychiatry 1973;130:922–4. http://dx.doi.org/10.1176/ajp.130.8.922
Friis T, Rosted-Christensen T, Gerlach J. Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism and hyperkinesia: a double-blind crossover study with placebo. Acta Psychiatr Scand 1983;67:178–87.
Gelenberg AJ, Wojcik J, Falk WE, Bellinghausen B, Joseph AB. CDP-choline for the treatment of tardive dyskinesia: a small negative series. Compr Psychiatry 1989;30:1–4.
Hemnani TJ, Dashputra PG, Sarda RN. Metoclopramide in tardive dyskinesia. Ind J Pharmacol 1982;14:309–12.
Hemanani TJ, Dashputra PG, Sarda RN. Metoclopramide in tardive dyskinesia. Ind J Psychiatry 1983;25:134–7.
Jeste DV, Cutler NR, Kaufmann CA, Karoum F. Low-dose apomorphine and bromocriptine in neuroleptic-induced movement disorders. Biol Psychiatry 1983;18:1085–91.
Joe SH, Suh KY, Lee BY. Effect of lecithin on tardive dyskinesia. Korea Uni Med J 1985;22:197–206.
Jus A, Villeneuve A, Gautier J, Jus K, Villeneuve C, Pires P, Villeneuve R. Deanol, lithium and placebo in the treatment of tardive dyskinesia. A double-blind crossover study. Neuropsychobiology 1978;4:140–9.
Korsgaard S. Baclofen (Lioresal) in the treatment of neuroleptic-induced tardive dyskinesia. Acta Psychiatr Scand 1976;54:17–24.
Lal S, Ettigi P. Comparison of thiopropazate and trifluoperazine on oral dyskinesia – a double blind study. Curr Ther Res Clin Exp 1974;16:990–7.
Lieberman J, Pollack S, Lesser M, Kane J. Pharmacologic characterization of tardive dyskinesia. J Clin Psychopharmacol 1988;8:254–60.
Lindenmayer JP, Gardner E, Goldberg E, Opler LA, Kay SR, van Praag HM, et al. High-dose naloxone in tardive dyskinesia. Psychiatry Res 1988;26:19–28.
Lohr JB, Cadet JL, Lohr MA, Larson L, Wasli E, Wade L, et al. Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms. Schizophr Bull 1988;14:291–6.
Lohr JB, Cadet JL, Lohr MA, Jeste DV, Wyatt RJ. Alpha-tocopherol in tardive dyskinesia. Lancet 1987;1:913–14.
Cadet JL, Lohr JB. Possible involvement of free radicals in neuroleptic-induced movement disorders. Evidence from treatment of tardive dyskinesia with vitamin E. Ann N Y Acad Sci 1989;570:176–85.
Nasrallah HA, Dunner FJ, McCalley-Whitters M, Smith RE. Pharmacologic probes of neurotransmitter systems in tardive dyskinesia: implications for clinical management. J Clin Psychiatry 1986;47:56–9.
Nordic Dyskinesia Study Group. Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Psychopharmacology 1986;90:423–9.
Gerlach J, Ahfors UG, Amthor KF. Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol and biperiden. Psychopharmacology 1986;90:423.
Gerlach J. Tardive dyskinesia. Pathophysiological mechanisms and clinical trials. Encephale 1988;14:227–32.
Povlsen UJ, Noring U, Meidahl B, Korsgaard S, Waehrens J, Gerlach J. [The effects of neuroleptics on tardive dyskinesias. A video-controlled, randomized study of chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden.] Ugeskr Laeg 1987;149:1682–5.
Penovich P, Morgan JP, Kerzner B, Karch F, Goldblatt D. Double-blind evaluation of deanol in tardive dyskinesia. JAMA 1978;239:1997–8.
Perez-Cruet J, Menendez I, Alvarez-Ghersi J, Falcon JR, Valderrabano O, Castro-Urrutia EC, et al. Double-blind study of lecithin in the treatment of persistent tardive dyskinesia. Boletin Asociacion Medica Puerto Rico 1981;73:531–7.
Ricketts RW, Singh NN, Ellis CR, Chambers S, Singh YN, Carmanico SJ, et al. Calcium channel blockers and vitamin E for tardive dyskinesia in adults with mental retardation. J Develop Phys Disabil 1995;7:161–74.
Shriqui CL, Bradwejn J, Annable L, Jones BD. Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study. Am J Psychiatry 1992;149:391–3.
Stearns AI, Sambunaris A, Elkashef AM, Issa F, Egan MF, Wyatt RJ. Selegiline for Negative Symptoms and Tardive Dyskinesia. Proceedings of the 149th Annual Meeting of the American Psychiatric Association, New York, NY, USA, 4–9 May 1996.
Tamminga CA, Chase TN. Bromocriptine and CF 25-397 in the treatment of tardive dyskinesia. Arch Neurol 1980;37:204–5.
Tamminga CA, Thaker GK, Ferraro TN, Hare TA. GABA agonist treatment improves tardive dyskinesia. Lancet 1983;2:97–8.
Tamminga CA, Thaker GK, Goldberg ST. Tardive Dyskinesia: GABA Agonist Treatment. In Usdin E, Carlsson A, Dahlstrom A, Engel J, editor(s). Catecholamines: Neuropharmacology and Central Nervous System – Therapeutic Aspects. New York, NY: Alan R Liss; 1984. pp. 69–72.
Thaker GK, Hare TA, Tamminga CA. GABA system: clinical research and treatment of tardive dyskinesia. Mod Probl Pharmacopsychiatry 1983;21:155–67.
Nguyen JA, Thaker GK, Tamminga CA. Gamma-aminobutyric-acid (GABA) pathways in tardive dyskinesia. Psychiatr Ann 1989;19:302–9.
Vaddadi KS, Courtney P, Gilleard CJ, Manku MS, Horrobin DF. A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia. Psychiatry Res 1989;27:313–23.
Vaddadi KS, Gileard CJ. Essential fatty acids, tardive dyskinesia, and schizophrenia. In Horrobin DF, ed. Omega-6 Essential Fatty Acids: Pathophysiology and Roles in Clinical Medicine. Hoboken, NJ: Wiley-Liss; 1990. pp. 333–43.
Wonodi I, Adami H, Sherr J, Avila M, Hong LE, Thaker GK. Naltrexone treatment of tardive dyskinesia in patients with schizophrenia. J Clin Psychopharmacol 2004;24:441–5.
Yamada K, Kanba S, Ashikari I, Ohnishi K, Yagi G, Asai M. Nilvadipine is effective for chronic schizophrenia in a double-blind placebo-controlled study. J Clin Psychopharmacol 1996;16:437–9.
Randomised, tardive dyskinesia, but crossover trial with no separate data reported for phase before crossing over to second treatment – no author contact details, study > 20 years old
Angus S, Sugars J, Boltezar R, Koskewich S, Schneider NM. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol 1997;17:88–91.
Auberger S, Greil W, Ruther E. Tiapride in the treatment of tardive dyskinesia. A double-blind study. Pharmacopsychiatry 1985;18:61–2.
Greil W, Auberger S, Haag H, Ruther E. Tiapride: effects on tardive dyskinesia and on prolactin plasma concentrations. Neuropsychobiology 1985;14:17–22.
Bateman DN, Dutta DK, McClelland HA, Rawlins MD. The effect of metoclopramide and haloperidol on tardive dyskinesia [proceedings.] Br J Pharmacol 1979;66:475P–476P.
Bateman DN, Dutta DK, McClelland HA, Rawlins MD. Metoclopramide and haloperidol in tardive dyskinesia. Br J Psychiatry 1979;135:505–8.
Braun A, Mouradian MM, Mohr E, Fabbrini G, Chase TN. Selective D-1 dopamine receptor agonist effects in hyperkinetic extrapyramidal disorders. J Neurol Neurosurg Psychiatr 1989;52:631–5.
Browne J, Silver H, Martin R, Hart R, Mergener M, Williams P. The use of clonidine in the treatment of neuroleptic-induced tardive dyskinesia. J Clin Psychopharmacol 1986;6:88–92.
Chien C, Jung K, Ross-Townsend A. Efficacies of agents related to GABA, dopamine, and acetylcholine in the treatment of tardive dyskinesia [proceedings.] Psychopharmacol Bull 1978;14:20–2.
Delwaide PJ, Desseilles M. [Controlled therapeutic study of spontaneous bucco-linguo-facial dyskinesias.] Sem Hop 1979;55:1585–9.
Gardos G, Granacher RP, Cole JO, Sniffin C. The effects of papaverine in tardive dyskinesia. Prog Neuropsychopharmacol 1979;3:543–50.
Gerlach J, Thorsen K, Munkvad I. Effect of lithium on neuroleptic-induced tardive dyskinesia compared with placebo in a double-blind cross-over trial. Pharmakopsychiatrie Neuro-Psychopharmakologie 1975;8:51–6.
Godwin-Austen RB, Clarke T. Persistant phenothiazine dyskinesia treated with tetrabenazine. Br Med J 1971;4:25–6.
Schwartz M, Moguillansky L, Lanyi G, Sharf B. Sulpiride in tardive dyskinesia. J Neurol Neurosurg Psychiatr 1990;53:800–2.
Silver H, Geraisy N, Schwartz M. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients. J Clin Psychiatry 1995;56:167–70.
Silver H, Geraisy N, Schwartz M. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients. J Clin Psychiatry 1995;56:435.
Singer K, Cheng MN. Thiopropazate hydrochloride in persistent dyskinesia. Br Med J 1971;4:22–5.
Singer K, Cheng MN. Thiopropazate Hydrochloride (Dartalan) in Persistent Dyskinesia with Phenothiazine Therapy. 5th World Congress of Psychiatry, Ciudad de Mexico, Mexico, 28 November–4 December 1971.
Viukari M, Linnoila M. Effect of methyldopa on tardive dyskinesia in psychogeriatric patients. Curr Ther Res Clin Exp 1975;18:417–24.
